- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Gastrostomy.
Displaying page 1 of 3.
EudraCT Number: 2007-001810-18 | Sponsor Protocol Number: 1503 | Start Date*: 2007-09-06 |
Sponsor Name:University Hospital Of North Staffordshire | ||
Full Title: Treatment of gastrostomy related granuloma using hydrocortisone or tea tree oil: A randomized controlled trial. | ||
Medical condition: Granulomas related to gastrostomy sites in children | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001983-39 | Sponsor Protocol Number: PHALS | Start Date*: 2017-09-28 |
Sponsor Name:University Medical Centre Utrecht | ||
Full Title: A placebo-controlled double blind randomized trial to investigate the efficacy and safety of the combination of Penicillin G / Hydrocortisone treatment in ALS patients (PHALS). | ||
Medical condition: Patients suffereing from Amytrophic Lateral Sclerosis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2011-001251-37 | Sponsor Protocol Number: 2011-011 | Start Date*: 2011-04-20 | |||||||||||
Sponsor Name:Vu Medical center | |||||||||||||
Full Title: Exploring alternative wound care treatment for percutanous gastrostomy site infection: a prospective, randomized, open, blinded end-point (PROBE) design. | |||||||||||||
Medical condition: Infection of the PEG(percutanous endoscopic gastrostomy)-insertion site. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004546-15 | Sponsor Protocol Number: ZP4207-17106 | Start Date*: 2018-08-24 | |||||||||||
Sponsor Name:Zealand Pharma A/S | |||||||||||||
Full Title: An Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon for the Treatment of Children with Congenital Hyperinsulinism | |||||||||||||
Medical condition: Children with congenital hyperinsulinism | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-017137-22 | Sponsor Protocol Number: 190178 | Start Date*: 2013-04-16 |
Sponsor Name:Klinische Abteilung für Thorax -u. Hyperbare Chirurgie, Medizinische Universität Graz | ||
Full Title: Clinical course after substitution of Vitamin-D deficiency in patients with lung cancer or oesophageal carcinoma. Double blind randomised prospective, placebo-controlled study. | ||
Medical condition: Patients admitted for treatment on a general thoracic surgery division with the following conditions: Lung cancer Esophageal cancer Cancer of the gastroesophageal junction (GEJ) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001077-87 | Sponsor Protocol Number: IJB-RT-HNC-001 | Start Date*: 2019-08-08 | |||||||||||
Sponsor Name:Institut Jules Bordet | |||||||||||||
Full Title: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced head and neck cancer patients t... | |||||||||||||
Medical condition: advanced head and neck cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004184-39 | Sponsor Protocol Number: BP39054 | Start Date*: 2017-09-05 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: AN OPEN-LABEL STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS/PHARMACODYNAMICS OF RO7034067 IN ADULT AND PEDIATRIC PATIENTS WITH SPINAL MUSCULAR ATROPHY | |||||||||||||
Medical condition: Spinal Muscular Atrophy (SMA) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Trial now transitioned) DE (Completed) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000095-38 | Sponsor Protocol Number: AVXS-101-CL-303 | Start Date*: 2020-03-18 |
Sponsor Name:AveXis, Inc. | ||
Full Title: Phase 3, Open-Label, Single-Arm, Single-Dose Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 with One or Two SMN2 Copies Delivering AVXS-101 by Intravenous ... | ||
Medical condition: Gene Replacement Therapy Clinical Trial for Patients with Spinal Muscular Atrophy Type 1 | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2017-000621-12 | Sponsor Protocol Number: ISIS396443-CS3A | Start Date*: 2017-02-15 |
Sponsor Name:Ionis Pharmaceuticals, Inc. | ||
Full Title: A Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of Multiple Doses of ISIS 396443 Delivered Intrathecally to Patients With Infantile-Onset Spinal Muscular Atrophy | ||
Medical condition: Spinal Muscular Atrophy (SMA) | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2014-002053-19 | Sponsor Protocol Number: CLMI070X2201 | Start Date*: 2014-12-16 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: An open-label multi-part first-in-human study of oral LMI070 in infants with Type 1 spinal muscular atrophy | |||||||||||||
Medical condition: Spinal Muscular Atrophy | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) IT (Completed) DE (Completed) BE (Completed) NL (Ongoing) CZ (Completed) PL (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002163-34 | Sponsor Protocol Number: TopROC | Start Date*: 2017-11-28 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: Comparative Effectiveness Trial of Transoral Head and Neck Surgery followed by adjuvant Radio(chemo)therapy versus primary Radiochemotherapy for Oropharyngeal Cancer (TopROC) | |||||||||||||
Medical condition: squamous cell carcinoma of the oropharynx | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000782-36 | Sponsor Protocol Number: AGO/2013/002 | Start Date*: 2013-08-13 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: Effect of TachoSil® on incidence of symptomatic and radiographic lymphoceles after extended pelvic lymph node dissection in prostate and bladder cancer. | |||||||||||||
Medical condition: Patients with prostate cancer or bladder cancer, undergoing transperitoneal pelvic lymph node dissection. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-002669-13 | Sponsor Protocol Number: 87RI21_0052 | Start Date*: 2022-11-25 | |||||||||||
Sponsor Name:Limoges University Hospital | |||||||||||||
Full Title: The PENTO protocol in Medication-related osteonecrosis of the jaw (MRONJ): a single-center phase IIa trial | |||||||||||||
Medical condition: Medication-related osteonecrosis of the jaw (MRONJ) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-001780-30 | Sponsor Protocol Number: GORTEC 2006-01 | Start Date*: 2007-02-28 | |||||||||||
Sponsor Name:UCL Saint Luc 1200 Bruxelles | |||||||||||||
Full Title: Etude de phase III du SU011248 chez les patients atteints d'un cancer épidermoïde de la tête et du cou en situation de rechute locorégionale et/ou métastatique | |||||||||||||
Medical condition: Cet essai s'adresse à des patients porteurs d'un carcinome épidermoïde de la tête et du cou en rechute locale ou en situation métastatique et qui ne peuvent plus bénéficier d'un traitement curatif | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001605-24 | Sponsor Protocol Number: GWND19002 | Start Date*: 2020-01-15 | |||||||||||
Sponsor Name:GW Research Ltd | |||||||||||||
Full Title: An open-label extension trial to investigate the long-term safety of cannabidiol oral solution (GWP42003-P, CBD-OS) in patients with Rett Syndrome | |||||||||||||
Medical condition: Rett syndrome (RTT) [typical or atypical] | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001534-13 | Sponsor Protocol Number: JAN13004-30 | Start Date*: 2015-10-02 | |||||||||||
Sponsor Name:SPHERIUM BIOMED S.L. | |||||||||||||
Full Title: Phase IB-II clinical trial of melatonin oral gel for the prevention and treatment of oral mucositis in patients with head and neck cancer undergoing chemoradiation. | |||||||||||||
Medical condition: Oral mucositis in patients with head and neck cancer undergoing chemoradiation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003767-23 | Sponsor Protocol Number: EGF105884 | Start Date*: 2006-07-13 |
Sponsor Name:GlaxoSmithKline Research & Development Limited | ||
Full Title: A Randomized, Double-Blind, Placebo-Controlled, Multicentre, Phase II Study of Oral Lapatinib in combination with Concurrent Radiotherapy and Cisplatin versus Radiotherapy and Cisplatin alone, in S... | ||
Medical condition: Stage III, IVa, IVb Squamous Cell Carcinoma of the Head & Neck | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) HU (Completed) ES (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-001506-29 | Sponsor Protocol Number: ML 18729 | Start Date*: 2005-10-10 | |||||||||||
Sponsor Name:Group of Clinical Investigation in Radiotherapy Oncology (GICOR) | |||||||||||||
Full Title: PHASE I/II TRIAL OF ERLOTINIB, RADIATIONTHERAPY, AND CISPLATIN IN PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK Ensayo Fase I/II de Erlotinib en combinación con radio... | |||||||||||||
Medical condition: PATIENTS WITH COMPLETE RESECTED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004723-37 | Sponsor Protocol Number: ONO-2506POE015 | Start Date*: 2008-05-16 | |||||||||||
Sponsor Name:ONO Pharmaceutical Co., Ltd. | |||||||||||||
Full Title: A Phase II multi-centre, extension study to investigate the long term safety of ONO-2506PO in patients diagnosed with Amyotrophic Lateral Sclerosis (ALS). | |||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis (ALS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) BE (Completed) FR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2023-000785-33 | Sponsor Protocol Number: HST20-CL01 | Start Date*: 2023-08-18 |
Sponsor Name:HemoShear Therapeutics | ||
Full Title: A Phase 2 Open-label, Dose Escalation Study of HST5040 in Subjects with Propionic or Methylmalonic Acidemia Followed by a 6-Month, Randomized, Double-blind, Placebo-controlled, 2-Period Crossover S... | ||
Medical condition: Methylmalonic Acidemia (MMA) Propionic Acidemia (PA) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
